These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 31324299)

  • 1. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Pardo S; Giovannoni G; Hawkes C; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2019 Aug; 33():A1-A2. PubMed ID: 31324299
    [No Abstract]   [Full Text] [Related]  

  • 2. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current Status and Prospects of Complement-Targeting Therapy for Neuromyelitis Optica].
    Kuroda H; Fujihara K
    Brain Nerve; 2019 Jun; 71(6):573-580. PubMed ID: 31171754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hope for a rare disease: eculizumab in neuromyelitis optica.
    Paul F
    Lancet Neurol; 2013 Jun; 12(6):529-31. PubMed ID: 23623398
    [No Abstract]   [Full Text] [Related]  

  • 6. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
    Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
    J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
    Pittock SJ; Fujihara K; Palace J; Berthele A; Kim HJ; Oreja-Guevara C; Nakashima I; Levy M; Shang S; Yountz M; Miller L; Armstrong R; Wingerchuk DM;
    Mult Scler; 2022 Mar; 28(3):480-486. PubMed ID: 34498507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
    Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
    Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Wingerchuk DM; Fujihara K; Palace J; Berthele A; Levy M; Kim HJ; Nakashima I; Oreja-Guevara C; Wang KC; Miller L; Shang S; Sabatella G; Yountz M; Pittock SJ;
    Ann Neurol; 2021 Jun; 89(6):1088-1098. PubMed ID: 33586143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab.
    Breu M; Glatter S; Höftberger R; Freilinger M; Kircher K; Kasprian G; Seidl R; Kornek B
    Neuropediatrics; 2019 Jun; 50(3):193-196. PubMed ID: 30913570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy.
    Barnett MH; Prineas JW; Buckland ME; Parratt JD; Pollard JD
    Mult Scler; 2012 Jan; 18(1):108-12. PubMed ID: 21868485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Topics of neuromyelitis optica].
    Miyamoto K
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):468-74. PubMed ID: 25748131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab in the treatment of neuromyelitis optica spectrum disorder.
    Giglhuber K; Berthele A
    Immunotherapy; 2020 Oct; 12(14):1053-1066. PubMed ID: 32772617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder.
    Olivieri G; Nociti V; Iorio R; Stefanini MC; Losavio FA; Mirabella M; Mariotti P
    Neurol Sci; 2015 Dec; 36(12):2301-2. PubMed ID: 26292790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.